Human CD52(CAMPATH-1 antigen) ELISA Kit

Name: Human CD52(CAMPATH-1 antigen) ELISA Kit
SKU: DEIA-FN252
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Serum, plasma, cell culture supernatant and other biological samples

Species Reactivity

Human

Detection Method

sELISA

Intended Use

In vitro quantitative determination of CD52 concentrations in serum, plasma, cell culture supernatant and other biological samples.

Storage

2-8°C (for sealed box), please do not freeze! See kit label for expiry date

Performance Characteristics

Perform the stability test for the sealed kit at 37°C and 2-8°C and get relevant data.

Precision

Intra-assay Precision: samples with low, medium and high concentration are tested 20 times on same plate.
Inter-assay Precision: samples with low, medium and high concentration are tested 20 times on three different plates.

Standard Curve

This product has been tested by Quality Control Department and meets performance specifications mentioned in the manual. (The humidity in the laboratory is 20%-60%, and the temperature is 18°C-25°C. TMB was balanced to 37°C before color development, and incubated at 37°C for 15 minutes in the dark after adding the enzyme label plate holes.)
The following assay data are provided for reference, since experimental environment and operation are different. The establishment of standard curve depends on your own assay.

Citations

Have you cited DEIA-FN252 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

A POLYCLONAL POPULATION OF PIGA MUTANT CD52 AND GPI-ANCHOR NEGATIVE T-CELLS CAN GIVE EARLY IMMUNE PROTECTION AFTER ALEMTUZUMAB-BASED T-CELL DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION

HAEMATOLOGICA

Authors: Loeff, F.; Falkenburg, J. F.; Hageman, L.; Veld, S.; de Meent, M. van; Halkes, S.; Jedema, I.

Abstract

Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery

CYTOTHERAPY

Authors: Gaertner, Frank; Hieke, Stefanie; Finke, Juergen; Bertz, Hartmut

Abstract

Background aims. The anti-CD52 monoclonal antibody alemtuzumab is employed in allogeneic hematopoietic cell transplantation (alloHCT) for the prevention of graft-versus-host disease (GVHD). However, its optimal dosing in this setting has not been determined yet. We compared three different alemtuzumab dose levels in reduced intensity conditioning (RIC) alloHCT with respect to lymphocyte recovery and outcome. Methods. In 127 consecutive patients with predominantly advanced stage hematologic malignancies, a first alloHCT after RIC was performed, applying a fludarabine-based protocol (in 93% FBM: fludarabine, bis-chloroethyl-nitrosourea [BCNU] and melphalan). For GVHD prophylaxis, cyclosporine and alemtuzumab at three different dose levels (40 mg, 20 mg, 10 mg) were administered. Recovery of the peripheral blood (PB) lymphocyte sub-populations and clinical outcome were determined with regard to the alemtuzumab dose. Results. Natural killer (NK) cell concentrations in PB around day +30 correlated inversely with the alerntuzumab dose, whereas other PB lymphocyte subtypes remained essentially unaffected by dosing of alemtuzumab. Lower alemtuzumab doses were associated with a tendency toward improved overall survival mainly during the early post-transplantation months. With regard to the PB NK cell concentration around day +30, "early intense NK cell reconstituters" tended to show an overall survival benefit. Conclusions. An alemtuzumab dose reduction to only 10-20 mg provides sufficient GVHD prophylaxis and supports improved NK cell regeneration early after alloHCT in PB ("NK cell saving effect"), which may have a positive effect on overall survival.